United StatesKris DeVault's three-year-old son, Brody, suffers from a rare genetic disorder called creatine transporter deficiency, which impairs his brain and muscle function. Despite the lack of approved treatments, DeVault is seeking access to an experimental drug developed by French biotech firm Ceres Brain Therapeutics. This drug, currently in early-stage development and untested in humans with Brody's condition, is being considered under Montana's 'right to try' law, which allows patients to access experimental treatments outside of traditional clinical trials. While the drug showed promise in animal studies and a phase I trial involving healthy adults, it has not been tested in individuals with CTD or children. DeVault believes this could be Brody's only chance for improvement.
Bias read (Center): The article presents a personal story centered on a family's struggle with a rare medical condition and their pursuit of an experimental treatment. While the 'right to try' law is discussed in the context of healthcare policy, the focus remains on individual experience rather than partisan debate. S
